Rovi: 2017 results preview: We expect a loss in 4Q17 as R&D and marketing increase
Rovi: 2017 results preview: We expect a loss in 4Q17 as R&D and marketing increase
Rovi will present its 12M2017 results on 20th February before the market opens, followed by a conference call at 15:00h CET.
- Sales to increase at mid single-digit rate
- And an EBITDA loss in 4Q
- Key issues to watch out for
- Recommendation: Hold
Laboratorios Farmaceuticos Rovi is engaged in the sale of its own pharmaceutical products and the distribution of other products for which it holds licenses granted by other laboratories for specific periods, in accordance with the terms and conditions contained in the agreements entered into with said laboratories.
Bankinter S.A. is a Spanish brokerage firm established in 1989. The company's line of business includes the provision of market research and trading services for Equity and Fixed Income products.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.